Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2012 |
| End Date: | January 2016 |
Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a
surrogate for tissue diagnosis of suspected primary lung cancer. This is done through
evaluating clinical and molecular markers to stratify the outcome/survival in patients with
thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of
California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.
surrogate for tissue diagnosis of suspected primary lung cancer. This is done through
evaluating clinical and molecular markers to stratify the outcome/survival in patients with
thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of
California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.
Inclusion Criteria:
- Suspected lung cancer
- Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an
intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed
- Age >18
Exclusion Criteria:
- Patients with history of a separate (not a primary lung cancer) malignancy within
past two years.
- Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc)
- Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years.
- Inability to provide informed consent.
- Hgb less than 8.
We found this trial at
3
sites
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials